ACR Share Price Performance
AU$0.014
-0.04 (-74.55%)
84.4% undervalued intrinsic discount
AU$0.09
Fair Value
Price AU$0.014
AnalystConsensusTarget AU$0.09
Fair ValueAU$0.09
Share PriceAU$0.014
84.4% undervalued intrinsic discount
Acrux Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
ACR Community Narratives
AN
Fair Value AU$0.09 84.4% undervalued intrinsic discount
New Product Launches Including Cone 75% Will Expand Market Presence
1users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
Acrux Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.015
- Gross Margin
- -93.95%
- Net Profit Margin
- -499.58%
- Debt/Equity Ratio
- 168.8%
Acrux Limited Competitors
Snowflake Analysis
About ACR
- Founded
- 1998
- Employees
- n/a
- CEO
- WebsiteView website
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain associated with chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Australian Market Performance
- 7 Days: 0.4%
- 3 Months: 5.4%
- 1 Year: 8.9%
- Year to Date: 9.7%
The market has climbed 1.2% in the last 7 days, lead by the Materials sector with a gain of 3.8%. The market is up 9.1% over the last 12 months. Earnings are forecast to grow by 12% annually. Market details ›